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ABSTRACT
Background Molecular methods based on
phylogenetic differences in the 16S rRNA gene are able
to characterise the microbiota of the respiratory tract in
health and disease.
Objectives Our goals were (1) to characterise
bacterial communities in lower and upper airways of
patients with interstitial lung disease (ILD) and (2) to
compare the results with the microbiota of patients with
Pneumocystis pneumonia (PCP) and normal controls.
Methods We examined the upper and lower
respiratory tract of 18 patients with ILD of whom 5, 6,
and 7 had idiopathic interstitial pneumonia (IIP), non-IIP
and sarcoidosis, respectively. In addition, six immune-
compromised patients with PCP and nine healthy
subjects were included as controls. Exclusion criteria
were recent bacterial/viral respiratory tract infection,
HIV-positivity and subjects receiving antibiotic therapy.
Bronchoalveolar lavage fluid and oropharyngeal
swabs were simultaneously collected, and microbiota
was characterised by ultra-deep 16S rRNA gene
sequencing.
Results The microbiota in lower airways of the majority
of patients (30; 90%) primarily consisted of
Prevotellaceae, Streptococcaceae and
Acidaminococcaceae. α and β diversity measurements
revealed no significant differences in airway microbiota
composition between the five different groups of
patients. Comparison of bacterial populations in upper
and lower respiratory tract showed
significant topographical discontinuities for 7 (23%)
individuals.
Conclusions IIP, non-IIP and sarcoidosis are not
associated with disordered airway microbiota and a
pathogenic role of commensals in the disease
process is therefore unlikely. Nevertheless, molecular
analysis of the topographical microbiota continuity
along the respiratory tract may provide additional
information to assist management of individual patients.
INTRODUCTION
Lower airways in healthy individuals have been
considered as being sterile based on conventional
microbial culture methods.1 2 This paradigm has
recently been challenged by studies implementing
ultra-deep sequencing methods analysing the 16S
rRNA gene. In particular, it has been suggested that
lower airways might be colonised with ‘symbiotic’
bacteria.3 4 Furthermore, it has been revealed that a
disturbance in the composition of the lower airway
microbiota may be associated with chronic lung dis-
eases, such as asthma or chronic obstructive lung
disease.3 5–8
A disturbance of the microbiota may also be
present in patients with interstitial lung disease
(ILD), but so far, this has not yet been investigated.
Though it is known that immune-compromised
hosts are at increased risk for lower respiratory
tract infections, the distinction between non-
infectious and infectious causes for deterioration of
an ILD patient can be clinically challenging based
on conventional microbiological diagnostic techni-
ques.9 An alteration of the airway microbiota in
ILD patients may hypothetically be associated with
clinical worsening due to immune dysregulation,
excessive inflammation and/or infection. The char-
acterisation of microbiota may therefore be of an
additional diagnostic value.
In the underlying study, we sought to investigate
the bacterial microbiota in the upper and lower
respiratory tract in patients with ILD. More specif-
ically, we aimed at addressing two objectives: (1) to
characterise bacterial communities in lower and
upper airways of patients with ILD and (2) to
compare the results with the microbiota of patients
with Pneumocystis pneumonia (PCP) and normal
controls.
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Key messages
What is the key question?
▸ Is the upper and lower airway microbiota of
patients with interstitial lung disease
disordered?
What is the bottom line?
▸ For the majority of patients with interstitial
lung disease, the lung microbiota is
comparable with normal controls.
Why read on?
▸ Using molecular methods, we describe the
microbiota of the upper and lower airways in
health and disease, which has the potential to
improve our understanding in the underlying
causes of lung diseases as compared with
conventional culture alone.
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MATERIAL AND METHODS
Study population and definitions
The Epidemiology and Clinical Relevance of Infectious Agents
in Bronchoalveolar Lavage (ECRIBAL) study is a prospective,
single centre observational study investigating new diagnostic
methods and potential pathogens in patients with ILD and in
immune-compromised patients with suspicion of lung infection.
The study has been approved by the local ethics committee
(Kantonale Ethikkommission Bern, approval Nr. 153/08).
For the purpose of the current microbiota study and based on
the ATS/ERS international multidisciplinary consensus classifica-
tion,10 we included patients of the following three ILD groups
from ECRIBAL: exacerbated idiopathic interstitial pneumonias
(IIP) (n=5), exacerbated non-IIP (n=6) and ILD due to sarcoid-
osis (n=7). Based on this classification, the non-IIP group con-
tained ILD due to known causes, such as collagen vascular
disease, environmental, drug related and ‘other’ ILD, for
example, eosinophilic pneumonia (see table 1 for details).
In addition, we included the following comparative groups:
patients with Pneumocystis pneumonia (PCP) (n=6) and healthy
controls without evidence for pulmonary or systemic disease
(n=9).
Enrolled individuals with an indication for bronchoscopy at
Bern University Hospital (Switzerland) had to be ≥18 years of
age and able to provide informed consent. Exclusion criteria for
this study were: recent bacterial/viral respiratory tract infection
within 2 weeks prior to bronchoalveolar lavage (BAL),
HIV-positivity and subjects that had received antibiotic therapy
within 48 h prior to BAL as this was previously shown to affect
the airway microbiota.11 12 The time difference between BAL
and lung function was normally 2 weeks. We initially selected
41 individuals out of whom 8 individuals from the following
groups had to be excluded due to absent amplification of lower
airway microbiota from BAL: sarcoidosis (n=3), non-IIP (n=3)
and controls (n=3).
BAL procedure and microbiological analysis
BAL was performed during bronchoscopy by wedging of the
bronchoscope tip in a segmental bronchus of the lobe that dis-
played radiological changes, followed by fractional instillation
and withdrawal of a total of 150 mL prewarmed saline using
50 mL syringes. Microbiological investigations in BAL consisted
of routine bacterial, fungal, viral and mycobacterial culture and
a panel of 15 respiratory viruses routinely detected (antigen
detection and/or PCR).13 Additional immunofluorescence and
PCR detection of P. jirovecii were performed as previously
described.14 Finally, oropharyngeal (OP) swabs were taken for
subsequent analysis of viruses and the microbiota of the upper
respiratory tract.
PCR amplification of the 16S rRNA genes
DNA extraction was performed using 200 μL of BAL sample
and the OP swab as previously described.15 16 V3–V5 regions of
bacterial 16S rRNA genes were amplified using the primer pairs
341F/926R.17 Primer sequences (bold) were modified by add-
ition of the Roche 454 Titanium sequencing A or B adaptor
sequence (lower cases) and a 10-mer multiplex identifier
(A-MID-341F, 50-cgtatcgcctccctcgcgccatcag-[NNNNNNNN
NN]-ACTCCTACGGGAGGCAGCAG-30; B-MID-926R,
50-ctatgcgccttgccagcccgctcag-[NNNNNNNNNN]-CCGTCAA
TTCMTTTGAGTTT-30. PCR reactions were performed and
purified using Wizard SV PCR clean-up system (Promega,
Madison) as described.17 The final elution step was performed
using 40 mL of double distilled water.
454 Titanium amplicon sequencing
Samples were pooled using 10 ng of PCR product of each
sample resulting in eight different pools including every multi-
plex identifier (MID) once. The amplicon libraries were
sequenced according to the 454 Titanium Amplicon Sequencing
protocols and a series of quality control steps were applied to
the resulting 454 reads.17 454 raw reads were submitted to the
NCBI Sequence Read Archive under the sequencing experiment
SRA026964 with the accession numbers SRX033134 and
SRX193716 (normal control samples).
Calculation of richness and Shannon diversity indices and
community comparisons (α and β diversity)
PyroTagger was used for the definition of operational taxonomic
units based on 97% sequence identity, estimation of chimaeras
and taxonomy assignments.18 α diversity analysis (including
richness, Shannon and Simpson Diversity indices) was
Table 1 ILD (IIP, non-IIP, sarcoidosis), PCP and control subgroups
used for analysis
IIP (n=5)
Age, year (mean±SD) 54.6±22.8
Sex, male (n) 2
Immunosuppressive therapy (n) 2
Detailed diagnosis IPF(2), UIP (2), COP (1),
FEV1% (range; mean±SD) 40–108; 74.8±24.5
FVC % (range; mean±SD) 42–118; 77.4±29.5
TLC % (range; mean±SD) 43–104; 76.2±27.8
Non-IIP (n=6)
Age, year (mean±SD) 56.0±17.9
Sex, male (n) 5
Immunosuppressive therapy (n) 3
Detailed diagnosis RA (1), asbestosis (1), EP (3), EAA (1)
FEV1% (range; mean±SD) 55–75; 65.5±8.2
FVC % (range; mean±SD) 58–85; 74.2±11.7
TLC % (range; mean±SD)* 52–94; 76.0±16.0
Sarcoidosis (n=7)
Age, year (mean±SD) 48.5±6.5
Sex, male (n) 6
Immunosuppressive therapy (n) 1
FEV1% (range; mean±SD) 60–136; 91.4±26.1
FVC % (range; mean±SD) 65–131; 99.6±28.1
TLC % (range; mean±SD) 59–122; 94.0±21.6
Pneumocystis pneumonia (PCP) (n=6)
Age, year (mean±SD) 58.3±10.6
Sex, male (n) 5
Immunosuppressive therapy (n) 6
FEV1% (range; mean±SD)† 56–101; 80.8±19.6
FVC % (range; mean±SD) † 52–115; 84.0±23.0
Normal controls (n=9)
Age, year (mean±SD) 57.6±11.4
Sex, male (n) 6
Immunosuppressive therapy (n) 0
*No TLC data available for patient (ID 12).
†No lung function data available for patient (ID 25) with Pneumocystis pneumonia.
COP, cryptogenic organising pneumonia; EAA, exogenous allergic alveolitis; EP,
eosinophilic pneumonia; FEV1%, forced expiratory volume in 1 s as a percentage of
the predicted value; FVC %, forced vital capacity as a percentage of the predicted
value; IIP, idiopathic interstitial pneumonia; ILD, interstitial lung disease;
IPF, idiopathic pulmonary fibrosis; non-IIP, non-idiopathic interstitial pneumonia;
RA, rheumatoid arthritis; TLC %, total lung capacity as a percentage of the predicted
value; UIP, usual interstitial pneumonia.
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performed employing Mothur.19 For the statistical analysis of
the α diversity results, ordinary one-way ANOVA and Mann–
Whitney analyses were performed. Resulting graphs were gener-
ated with GraphPad Prism V.5.02 (GraphPad Software, Inc, La
Jolla, California, USA).
Community comparisons were calculated using non-metric
multidimensional scaling (nMDS) and the adonis function of
the vegan package in R as previously described.17 For the cre-
ation of the input distance matrices, binary and abundance-
based (Horn) calculations were performed as previously
described.17 20 Procrustes function of R was used to compare
the nMDS plots between the upper and lower respiratory tract.
Ordinary one-way ANOVA was performed to investigate the
significant differences of the relative mean abundances of bacter-
ial families of the upper and lower airways.
RESULTS
Study patients, PCR amplification and 16S rRNA gene
pyrosequencing
Clinical characteristics of the 33 patients are summarised in
table 1. The study subjects had an overall mean age of 55.2
±13.7 years and were categorised into the following groups: IIP,
non-IIP, sarcoidosis, PCP and healthy controls. Nine (27.3%)
were women, sarcoidosis was the most frequent ILD diagnosis
(n=7) and none of the 33 study subjects received antibiotic
treatment within 48 h before BAL. Though amplification of the
33 BAL samples revealed that the bacterial quantity of controls
was lower, this was not statistically significant. Subsequent 16S
rRNA gene pyrosequencing was performed and estimates
revealed that sequencing depth was approximately 80% (data
not shown).
α Diversity measurements in lower airways
In order to investigate if microbiota composition varied between
patients with different manifestations of ILD, we initially calcu-
lated bacterial richness and Shannon diversity indices of the
lower airways, that is, in samples obtained from BAL (α diver-
sity; figure 1). Both indices are ideal measurements to easily and
rapidly investigate alterations in the microbiota as they result in
a numeric value that may serve as a surrogate marker for disor-
dered microbial communities. This value decreases when a
single bacterial species has ‘overgrown’ and become predomin-
ant, replacing the classic ‘commensal’ microbiota.
The mean richness values were 56.2 (±29.2), 83.7 (±20.6),
75.1 (±25.9), 60.3 (±16.4) and 63.3 (±20.3) for IIP, non-IIP,
sarcoidosis, PCP and normal controls, respectively (figure 1A).
The lowest value was therefore found for IIP but this finding
was not statistically significant compared with the other groups.
As for the Shannon diversity indices, again, patients with IIP
had the lowest values (mean 2.0±1.1) (figure 1B), but differ-
ences among the indices were again not significantly different
performing both ordinary one-way ANOVA and Mann–Whitney
analyses (figure 1A).
β Diversity measurements in lower airways
We then measured pairwise distances between microbial com-
munities of all 33 samples. For this, Bray–Curtis distance matri-
ces were used as input and the amount of variance was
calculated (β diversity calculations). Overall bacterial communi-
ties in lower airways did not significantly differ in patients with
IIP, non-IIP, sarcoidosis, PCP and controls (figure 2). However,
five patients had a clearly different bacterial profile (ID 64, 53,
73, 108 and 50; figure 2).
Relative abundance of bacterial families and quantification
Sequencing results and subsequent taxa assignments for all 33
BAL samples are illustrated in figure 3. The communities of
three patients harboured solitary abundances of Neisseriaceae
(patient ID 50), Streptococcaceae (patient ID 73) and
Pasteurellaceae (patient ID 64) (figure 3). However, the micro-
biota of the 30 remaining patients primarily consisted of bacter-
ial families known as commensals, that is, non-pathogenic
bacteria colonising the airways. Such commensals included
Prevotellaceae, Streptococcaceae and Acidaminococcaceae. Due
to the nature of the bacterial families present, this again indi-
cated that the microbiota may not be disturbed in IIP, non-IIP,
sarcoidosis and PCP as compared with healthy controls. In add-
ition, a more detailed investigation of the relative differences of
the bacterial families revealed that the clinical diagnosis (IIP,
non-IIP, sarcoidosis, PCP or controls) is only significantly asso-
ciated with the relative mean abundance of Flavobacteriaceae
(table 2). For all other families, no significant differences were
detected (table 2).
Figure 1 α-Diversity indices of the lower airway microbiota. Indicated
are the Richness (A) and Shannon-diversity (B) indices for subjects with
idiopathic interstitial pneumonia (IIP), non-idiopathic interstitial
pneumonia (non-IIP), sarcoidosis, Pneumocystis pneumonia (PCP) and
normal controls. No significant differences were observed.
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Analysis of topographical continuity along the respiratory
tract
We subsequently analysed the upper respiratory tract (orophar-
ynx) of the 33 subjects (figure 3; right column). As for the
lower airways, Prevotellaceae was the most abundant bacterial
family followed by Streptococcaceae and Acidaminococcaceae.
In a next step, we quantified differences between upper and
lower respiratory tract communities in order to analyse topo-
graphical continuity. Assuming that a normal respiratory tract
has similar or concordant microbiota profiles between upper
and lower airways,4 a divergence would be indicative of the
presence of disordered microbial communities at the site of
Figure 3 Microbial community comparisons and relative abundances of the top 20 bacterial families in 33 bronchoalveolar lavage (BAL) and
oropharyngeal samples. A tree illustrating similarities of the microbial communities of the BAL samples are shown on the left. Abundances of
bacterial families for each subject (ID) are indicated by a greyscale value. The five groups consisting of idiopathic interstitial pneumonia (IIP),
non-idiopathic interstitial pneumonia (non-IIP), sarcoidosis, Pneumocystis pneumonia (PCP) and normal controls, as well as if immunocompromised
(IC) for each study subject are indicated. The quantities of bacterial species derived from conventional culture are provided in colony forming units
(CFU). The concentrations of the amplification products (c) are indicated in ng/μL.
Figure 2 Comparison of bacterial
communities in the lower airways by a
non-metric multidimensional scaling
ordination plot. Shown are the results
for subjects with idiopathic interstitial
pneumonia (IIP), non-idiopathic
interstitial pneumonia (non-IIP),
sarcoidosis, Pneumocystis pneumonia
(PCP) and normal controls. Bray–Curtis
distance matrices were used as input.
Statistical differences between the five
groups were non-significant (ie, small
distances between central points). Five
patients had different microbiota
illustrated by the large distances to the
central points (ID 64, 53, 73, 108 and
50). nMDS, non-metric
multidimensional scaling.
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interest. Using procrustes analysis we revealed that 7 of 33
patients (ID 17, 38, 50, 53, 64, 73 and 108) displayed differ-
ences exceeding the upper quantile of procrustes errors, suggest-
ing a significant disordered microbiota between the upper and
lower respiratory tract (figure 4).
We then analysed clinical characteristics of the seven patients
with topographical microbiota discontinuity. Patient 38 had mainly
commensal Corynebacteriaceae in the oropharynx, but essentially
harbouring ‘normal’ Prevotellaceae, Acidaminococcaceae and
Streptococcaceae in the BAL. Therefore, this subject could be
Figure 4 Comparison of the
microbiota between upper and lower
airways by procrustes analysis.
Pairwise distance matrices were
calculated between lower and upper
microbial respiratory tract communities
from which non-metric dimension plots
were subsequently derived. Patients
with procrustes residual exceeding the
upper quantile (upper dashed line)
were considered as containing different
microbial communities (ID 64, 50, 73,
38, 53, 17 and 108). Study subjects
are presented according to the clinical
diagnosis: sarcoidosis, idiopathic
interstitial pneumonia (IIP),
non-idiopathic interstitial pneumonia
(non-IIP), Pneumocystis pneumonia
(PCP) and normal controls. ILD,
interstitial lung disease.
Table 2 Relative mean abundances of bacterial families in lower and upper airways
Lower airways Upper airways
Relative mean abundance in % Relative mean abundance in %
Bacterial families
IIP
(n=5)
non-IIP
(n=6)
Sarcoidosis
(n=7)
PCP
(n=6)
Control
(n=9)
p
Value*
IIP
(n=5)
non-IIP
(n=6)
Sarcoidosis
(n=7)
PCP
(n=6)
Control
(n=9)
p
Value*
Moraxellaceae 0.1 0.1 0.0 0.4 1.8 0.068 2.2 0.0 0.0 0.0 1.2 0.456
Comamonadaceae 0.1 0.8 0.2 1.3 0.4 0.274 0.8 0.0 0.6 0.0 0.6 0.727
Cellulomonadaceae 0.0 0.0 0.0 11.8 0.0 0.357 0.0 0.0 0.0 0.0 0.0 1.000
Aerococcaceae 0.8 1.3 0.6 0.8 0.5 0.488 0.4 3.0 0.9 3.1 1.2 0.428
Rhizobiaceae 0.1 1.4 0.4 1.4 0.4 0.191 0.2 0.1 0.4 0.0 1.2 0.462
Lactobacillaceae 0.1 0.0 0.0 0.0 1.3 0.560 0.8 0.0 0.1 0.0 0.8 0.413
Nocardiaceae 0.4 1.2 0.4 1.8 0.1 0.058 0.0 0.2 0.5 0.1 0.1 0.626
Capnocytophagaceae 0.1 2.2 0.6 3.1 0.9 0.239 1.9 0.4 1.0 2.2 0.7 0.522
Microbacteriaceae 0.4 1.4 0.5 1.2 0.1 0.061 0.1 0.1 1.0 0.2 0.1 0.585
Sphingomonadaceae 0.1 0.5 0.2 0.4 0.2 0.388 0.1 0.2 0.1 0.0 0.3 0.509
Flavobacteriaceae 1.1 4.3 1.3 4.7 0.4 0.036 0.2 0.5 1.2 8.1 0.2 0.048
Peptostreptococcaceae 1.3 1.0 1.0 0.7 1.1 0.931 0.9 0.6 1.6 0.3 0.3 0.184
Fusobacteriaceae 1.9 7.3 5.9 2.0 6.4 0.282 2.1 3.5 6.3 11.8 6.2 0.442
Staphylococcaceae 0.0 1.5 1.0 5.9 0.5 0.313 0.4 2.4 3.2 7.8 0.7 0.355
Porphyromonadaceae 2.8 5.3 4.1 11.5 2.8 0.586 4.1 2.3 8.1 5.7 2.0 0.147
Pasteurellaceae 19.0 4.0 2.5 4.3 1.1 0.345 2.0 3.4 2.7 39.3 1.4 0.412
Neisseriaceae 16.2 4.2 4.7 9.2 6.6 0.686 22.5 1.1 6.1 10.5 4.5 0.281
Acidaminococcaceae 4.7 15.0 12.1 5.1 6.2 0.114 9.3 10.2 6.6 10.1 5.3 0.771
Streptococcaceae 4.3 10.3 21.6 4.2 17.4 0.380 12.6 10.9 9.6 7.6 22.0 0.090
Prevotellaceae 39.3 26.8 37.0 24.7 42.0 0.760 32.3 33.9 35.1 24.8 40.9 0.767
*p Values derived by ordinary one-way analysis of variance are indicated. p<0.05 is considered as being significant indicating a difference between the five groups.
IIP, idiopathic interstitial pneumonia; non-IIP, non-idiopathic interstitial pneumonia; PCP, Pneumocystis pneumonia.
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considered as healthy in the absence of clinical signs and symptoms
indicative of an upper respiratory tract infection. The high procrus-
tes residuals in patients 17 and 64 have their origins in the high
abundances of Pasteurellaceae (ie, Haemophilus influenzae as con-
firmed by culture) in the upper (patient 17) and lower (patient 64)
respiratory tract (figure 3). H. influenzae is frequently detected in
microbial cultures, but it is often unclear if this reflects non-
pathogenic colonisation or infection, given that different strains
with both features are known.21 In our study, we identified
H. influenzae in patients 17, 25 and 64, but only in patient 64, the
overall microbiota was disordered in the lower respiratory tract,
suggesting infection rather than colonisation (figure 3). Patient 64
was diagnosed with idiopathic pulmonary fibrosis without evidence
by conventional microbiology for respiratory tract infection and
did not improve under an initial course of systemic corticosteroid
treatment. Based on the microbiota results of the lower airways,
H. influenzae may have played a clinically relevant role in the
course of the exacerbation, and therefore, in the absence of the
‘normal’ microbiota, an initial antibiotic treatment may have been
an appropriate treatment option.
The remaining procrustes differences occurred in patients 50,
53, 73 and 108. These were based on excess abundance of
Streptococcus pneumoniae (patient 73), Neisseriaceae (patient
50 and normal control 108) and Cellulomonadaceae (mainly
Tropheryma whipplei, patient 53) and were localised to the
lower airways. In patient 73 with a histologically proven sarcoid-
osis, microbiota discontinuity was present with an excess of
S. pneumoniae, but without signs for respiratory tract infection.
This finding, together with the excess Neisseriaceae in patients
50 and 108, remains unclear. Finally, identification of
Cellulomonadaceae (mainly T. whipplei) in patient 53 is an intri-
guing finding and may be due to hitherto undiagnosed
Whipple’s Disease.
DISCUSSION
Recent studies using 16S rRNA gene pyrosequencing techniques
have explored the microbiota of the lower and upper respiratory
tract in health and disease.3 4 22 23 These techniques now also
enable to investigate disordered microbial communities in
patients with other lung disorders and conditions, such as IIP,
non-IIP and sarcoidosis, which to our knowledge, has not been
performed to date. Within this study, we therefore aimed at
characterising the bacterial communities in lower and upper
airways of patients with IIP, non-IIP and sarcoidosis and to
compare the results with the microbiota of patients with
Pneumocystis pneumonia (PCP) and normal controls.
Most of the patients with IIP, non-IIP, sarcoidosis and PCP har-
boured three bacterial families (Prevotellaceae, Streptococcaceae
and Acidaminococcaceae) in the respiratory tract that were also
frequently detected in healthy controls, and therefore, indicated
that no disordering of the microbiota was present. It is worth-
while mentioning that the same commensal families have also
been reported in other recent studies analysing the healthy
respiratory tract.3 4
α and β diversity measurements are available to investigate if
clinical factors and/or diagnoses are significantly associated with
an altered microbiota composition. In our study, neither α nor β
diversity indices revealed any significant changes related to the
clinical diagnosis of IIP, non-IIP, sarcoidosis or PCP compared
with healthy controls.
To date, sound data linking microbiota changes to lung disor-
ders are still scarce as this field of research is still in its infancy.
In HIV-infected patients, several known or suspected pathogenic
organisms have been detected that may be related to recurrent
pneumonia.11 In patients with non-CF bronchiectasis, character-
istics of the lower airways microbiota correlated with clinical
markers of disease severity.23 Finally, two studies revealed that
the microbiota in cystic fibrosis patients is distinct, probably due
to the specific environmental characteristics in the respiratory
tract of these patients.24 25
In our study, we simultaneously analysed upper and lower
respiratory tract, which is an important aspect for two reasons:
first, this approach allows the examination for possible contam-
ination from the upper respiratory tract.26 Second, it enables to
specifically localise microbial communities in the airways as
shown by recent studies.5 27 For the healthy human respiratory
tract, topographical continuity of bacterial populations has pre-
viously been described.4 Within our study, we now extend these
findings by demonstrating that continuity of microbiota also
exists in the majority of patients with underlying ILD. This
finding was not applicable for seven individuals revealing signifi-
cant divergence between the upper and lower respiratory tract.
This may indicate disturbed microbiota in the upper or lower
airways, but has to be investigated for each patient separately.
Based on our data, we suggest that the identification of micro-
biota discontinuity along the respiratory tract should generally
be interpreted by taking into account the clinical presentation of
the patient.
Compared with conventional bacterial cultures, utilisation of
pyrosequencing methods generally has two advantages. First, the
methods are able to identify unusual pathogenic bacteria nor-
mally not detectable by conventional microbiological
methods.28–30 Second, these methods can assist to identify the
pathogenic role of ‘commensal’ bacteria. Depletion of the
normal microbiota with ‘overgrowth’ of a single bacterial species
may indicate that this is clinically relevant, for example, as seen
with H. influenzae in our study. This is an important aspect as the
clinician is commonly confronted with the challenge to distin-
guish between innocuous commensals, ‘facultative pathogenic’
and ‘pathogenic’ bacteria. However, it is crucial to emphasise
that conventional culture and molecular methods should be seen
as complimentary, rather than exclusionary, as molecular
methods may detect difficult-to-culture bacteria but may in turn
miss potentially pathogenic bacteria in low abundance, as these
may not significantly alter microbial communities.
There are several limitations to our study. First, based on the
ATS/ERS ILD classification into different groups, subjects pre-
sented with a certain degree of heterogeneity within this study.
Nevertheless, we feel that selecting the five groups, we have
compared clinically relevant populations. Second, we did not
perform extensive ultra-deep sequencing of viruses and fungi in
the collection of samples. Although this has recently been
shown to be feasible, fungi identified by this technique were
mostly cultivated and known.31 We routinely searched for 15
respiratory viruses, for Pneumocystis jirovecii by immunofluores-
cence and PCR, measured galactomannan levels and cultured
fungi and mycobacteria. We are therefore confident that we did
not neglect clinically relevant and currently known pathogens.
Third, the number of patients included in this feasibility study is
relatively low; therefore, a potential added benefit of character-
ising microbiota to distinguish between presence of a relevant
pathogen and non-infectious clinical worsening in an ILD
patient requires further evaluation in prospective, larger studies.
Finally, this study includes patients with exacerbated IIP and
non-IIP. As we did not include samples from IIP and non-IIP
patients during disease stability, we were therefore not able to
investigate longitudinal microbiota changes during the actual
exacerbation within this study. Nevertheless, considering that we
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did not detect significant microbiota differences in exacerbated
ILD patients compared with normal controls, we hypothesise
that changes from an ILD-driven microbiota towards a ‘normal’
microbiota during exacerbation is unlikely and that the presence
of a ‘normal’ microbiota during times of stability would be
more probable. In agreement with this hypothesis, significant
changes in community structure or diversity were not observed
at the time of exacerbation in adults with cystic fibrosis.32 33
We conclude that 16S rRNA gene-based pyrosequencing is
able to characterise microbial communities in upper and lower
airways in ILD patients, but the diagnosis of IIP, non-IIP, sarcoid-
osis or during PCP per se did not alter the overall lung micro-
biota. Analysis of the topographical continuity along the
respiratory tract may provide important additional information
to assist the physician in understanding the underlying cause of
clinical worsening in ILD patients, a process that will always
involve distinguishing infectious from non-infectious causes of
inflammation. A potential future application of 16S rRNA gene-
based pyrosequencing is the search of hitherto insufficiently
known bacteria that may be relevant in the pathogenesis and
course of pulmonary disease.
Acknowledgements We thank the Professors Jean-Francois Dufour, Martin Fey,
Felix Frey, Thomas Geiser, Paul Mohacsi and Peter Villiger for their help in providing
clinical data and Cornelia Wyss, Monika Wüthrich and Liselotte McEvoy for their
assistance with patient recruitment and administrative tasks. We are also grateful to
Irène Stutz and Heidi Pfäffli for technical assistance and sample processing.
Contributors Conception and design: CG, SDB, KM, MG-H. Acquisition of data:
CG, SDB, WQ, SW, AC, PD, CvG, MG-H. Analysis and interpretation: CG, SDB, CvG,
MG-H. Drafting the manuscript: CG, SDB, WQ, MG-H, CvG, MH.
Funding This study was supported by unrestricted grants (AstraZeneca, Roche,
MSD, Essex Chemie Switzerland, Wyeth, Astellas to C.G.), the Swiss National
Science Foundation (M.D.-Ph.D. scholarship 323500-119214 to S.D.B. and Sinergia
CRSII3-141875 to M.H. and C.v.G) and the 2012 Award of the Swiss Society of
Hospital Hygiene & the Swiss Society for Infectious Diseases (to M.H.).
Competing interests None.
Patient consent Obtained.
Ethics approval Kantonale Ethikkommission Bern, approval Nr. 153/08.
Provenance and peer review Not commissioned; externally peer reviewed.
Open Access This is an Open Access article distributed in accordance with the
Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which
permits others to distribute, remix, adapt, build upon this work non-commercially,
and license their derivative works on different terms, provided the original work is
properly cited and the use is non-commercial. See: http://creativecommons.org/
licenses/by-nc/3.0/
REFERENCES
1 Laurenzi GA, Potter RT, Kass EH. Bacteriologic flora of the lower respiratory tract.
N Engl J Med 1961;265:1273–8.
2 Pecora DV. A comparison of transtracheal aspiration with other methods of
determining the bacterial flora of the lower respiratory tract. N Engl J Med
1963;269:664–6.
3 Hilty M, Burke C, Pedro H, et al. Disordered microbial communities in asthmatic
airways. PLoS One 2010;5:e8578.
4 Charlson ES, Bittinger K, Haas AR, et al. Topographical continuity of bacterial
populations in the healthy human respiratory tract. Am J Respir Crit Care Med
2011;184:957–63.
5 Erb-Downward JR, Thompson DL, Han MK, et al. Analysis of the lung microbiome
in the “healthy” smoker and in COPD. PLoS One 2011;6:e16384.
6 Han MK, Huang YJ, Lipuma JJ, et al. Significance of the microbiome in obstructive
lung disease. Thorax 2012;67:456–63.
7 Pragman AA, Kim HB, Reilly CS, et al. The lung microbiome in moderate and severe
chronic obstructive pulmonary disease. PLoS One 2012;7:e47305.
8 Sze MA, Dimitriu PA, Hayashi S, et al. The lung tissue microbiome in chronic
obstructive pulmonary disease. Am J Respir Crit Care Med 2012;185:1073–80.
9 Carroll KC. Laboratory diagnosis of lower respiratory tract infections: controversy and
conundrums. J Clin Microbiol 2002;40:3115–20.
10 American Thoracic Society/European Respiratory Society International
Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias.
This joint statement of the American Thoracic Society (ATS), and the European
Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001
and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med
2002;165:277–304.
11 Iwai S, Fei M, Huang D,, et al Oral and airway microbiota in HIV-infected
pneumonia patients. J Clin Microbiol 2012;50:2995–3002.
12 Jakobsson HE, Jernberg C, Andersson AF, et al. Short-term antibiotic treatment has
differing long-term impacts on the human throat and gut microbiome. PLoS One
2010;5:e9836.
13 Garcia LS. Clinical microbiology procedures handbook. 3rd edn. ASM Press, 2010.
14 Muhlethaler K, Bogli-Stuber K, Wasmer S, et al. Quantitative PCR to diagnose
Pneumocystis pneumonia in immunocompromised non-HIV patients. Eur Respir J
2012;39:971–8.
15 Brugger SD, Frei L, Frey PM, et al. 16S rRNA terminal restriction fragment length
polymorphism for the characterization of the nasopharyngeal microbiota. PLoS One
2012;7:e52241.
16 Brugger SD, Hathaway LJ, Muhlemann K. Detection of Streptococcus pneumoniae
strain cocolonization in the nasopharynx. J Clin Microbiol 2009;47:1750–6.
17 Hilty M, Qi W, Brugger SD, et al. Nasopharyngeal microbiota in infants with acute
otitis media. J Infect Dis 2012;205:1048–55.
18 Kunin V, Hugenholtz P. PyroTagger: a fast, accurate pipeline for analysis of rRNA
amplicon pyrosequence data. The Open Journal 2010:1–8.
19 Schloss PD, Westcott SL, Ryabin T, et al. Introducing mothur: open-source,
platform-independent, community-supported software for describing and comparing
microbial communities. Appl Environ Microbiol 2009;75:7537–41.
20 Frank DN, Feazel LM, Bessesen MT, et al. The human nasal microbiota and
Staphylococcus aureus carriage. PLoS One 2010;5:e10598.
21 King P. Haemophilus influenzae and the lung (Haemophilus and the lung). Clin
Transl Med 2012;1:10.
22 Cardenas PA, Cooper PJ, Cox MJ, et al. Upper airways microbiota in antibiotic-naive
wheezing and healthy infants from the tropics of rural Ecuador. PLoS One 2012;7:
e46803.
23 Rogers GB, van der Gast CJ, Cuthbertson L, et al. Clinical measures of disease in
adult non-CF bronchiectasis correlate with airway microbiota composition. Thorax
2013;68:731–7.
24 Lipuma JJ. The changing microbial epidemiology in cystic fibrosis. Clin Microbiol Rev
2010;23:299–323.
25 Rogers GB, Hoffman LR, Carroll MP, et al. Interpreting infective microbiota: the
importance of an ecological perspective. Trends Microbiol 2013;21:271–6.
26 Goddard AF, Staudinger BJ, Dowd SE, et al. Direct sampling of cystic fibrosis lungs
indicates that DNA-based analyses of upper-airway specimens can misrepresent lung
microbiota. Proc Natl Acad Sci USA 2012;109:13769–74.
27 Willner D, Haynes MR, Furlan M, et al. Spatial distribution of microbial communities
in the cystic fibrosis lung. ISME J 2012;6:471–4.
28 Bousbia S, Papazian L, Auffray JP, et al. Tropheryma whipplei in patients with
pneumonia. Emerg Infect Dis 2010;16:258–63.
29 Harris JK, De Groote MA, Sagel SD, et al. Molecular identification of bacteria in
bronchoalveolar lavage fluid from children with cystic fibrosis. Proc Natl Acad Sci
U S A 2007;104:20529–33.
30 Duff RM, Simmonds NJ, Davies JC, et al. A molecular comparison of microbial
communities in bronchiectasis and cystic fibrosis. Eur Respir J 2013;
41:991–3.
31 Charlson ES, Diamond JM, Bittinger K, et al. Lung-enriched organisms and aberrant
bacterial and fungal respiratory microbiota following lung transplant. Am J Respir
Crit Care Med 2012;186:536–45.
32 Stressmann FA, Rogers GB, van der Gast CJ, et al. Long-term
cultivation-independent microbial diversity analysis demonstrates that bacterial
communities infecting the adult cystic fibrosis lung show stability and resilience.
Thorax 2012;67:867–73.
33 Zhao J, Schloss PD, Kalikin LM, et al. Decade-long bacterial community dynamics in
cystic fibrosis airways. Proc Natl Acad Sci USA 2012;109:5809–14.
1156 Garzoni C, et al. Thorax 2013;68:1150–1156. doi:10.1136/thoraxjnl-2012-202917
Respiratory infection
 group.bmj.com on January 24, 2014 - Published by thorax.bmj.comDownloaded from 
doi: 10.1136/thoraxjnl-2012-202917
 2013 68: 1150-1156 originally published online August 14, 2013Thorax
 
Christian Garzoni, Silvio D Brugger, Weihong Qi, et al.
 
diseasetract of patients with interstitial lung 
Microbial communities in the respiratory
 http://thorax.bmj.com/content/68/12/1150.full.html
Updated information and services can be found at: 
These include:
References
 http://thorax.bmj.com/content/68/12/1150.full.html#ref-list-1
This article cites 31 articles, 14 of which can be accessed free at:
Open Access
non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/
terms, provided the original work is properly cited and the use is
work non-commercially, and license their derivative works on different 
license, which permits others to distribute, remix, adapt, build upon this
Creative Commons Attribution Non Commercial (CC BY-NC 3.0) 
This is an Open Access article distributed in accordance with the
service
Email alerting
the box at the top right corner of the online article.
Receive free email alerts when new articles cite this article. Sign up in
Collections
Topic
 (40 articles)Fungal lung diseases   
 (438 articles)Pneumonia (respiratory medicine)   
 (1022 articles)TB and other respiratory infections   
 (451 articles)Pneumonia (infectious disease)   
 (760 articles)Drugs: infectious diseases   
 (154 articles)Chemotherapy   
 (404 articles)Interstitial lung disease   
 (93 articles)Open access   
 
Articles on similar topics can be found in the following collections
 http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
 http://journals.bmj.com/cgi/reprintform
To order reprints go to:
 http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
 group.bmj.com on January 24, 2014 - Published by thorax.bmj.comDownloaded from 
Notes
 http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
 http://journals.bmj.com/cgi/reprintform
To order reprints go to:
 http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
 group.bmj.com on January 24, 2014 - Published by thorax.bmj.comDownloaded from 
